iTeos Therapeutics, Inc. (ITOS)
10.15
+0.02 (0.20%)
Inactive · Last trade price on Aug 28, 2025
iTeos Therapeutics Employees
iTeos Therapeutics had 173 employees as of December 31, 2024. The number of employees increased by 16 or 10.19% compared to the previous year.
Employees
173
Change (1Y)
16
Growth (1Y)
10.19%
Revenue / Employee
n/a
Profits / Employee
-$1,170,006
Market Cap
448.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 173 | 16 | 10.19% |
| Dec 31, 2023 | 157 | 32 | 25.60% |
| Dec 31, 2022 | 125 | 31 | 32.98% |
| Dec 31, 2021 | 94 | 32 | 51.61% |
| Dec 31, 2020 | 62 | 19 | 44.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
ITOS News
- 5 weeks ago - ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS - GlobeNewsWire
- 2 months ago - ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS - Business Wire
- 2 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc. - PRNewsWire
- 2 months ago - iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right - GlobeNewsWire
- 4 months ago - iTeos Therapeutics Announces Its Intention to Wind Down Operations - GlobeNewsWire
- 4 months ago - iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 5 months ago - iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewsWire